Catalyst Pharmaceuticals (CPRX) Proxy filing summary

Executive summary

• Announced agreement for acquisition by Angelini Pharma, with closing expected in Q3 2026.

• First quarter 2026 revenues reached $149.4 million, a 28.2% year-over-year increase, driven by FIRDAPSE and AGAMREE.

• Integration planning with Angelini Pharma is underway, with both companies operating independently until closing.

• Employees are encouraged to maintain business as usual during the transition period.

• Forward-looking statements highlight expectations, integration plans, and potential risks related to the transaction.

Voting matters and shareholder proposals

• Shareholders will be asked to approve the merger with Angelini Pharma, as detailed in the forthcoming proxy statement.

• Proxy materials will be distributed to security holders, urging them to review all documents before voting.

Board of directors and corporate governance

• Directors and executive officers of both companies may participate in the proxy solicitation.

• Information on directors’ and officers’ interests will be disclosed in the proxy statement and recent annual filings.